Penetrance

Revision as of 17:31, 25 June 2009 by Mdoherty (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

WikiDoc Resources for Penetrance

Articles

Most recent articles on Penetrance

Most cited articles on Penetrance

Review articles on Penetrance

Articles on Penetrance in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Penetrance

Images of Penetrance

Photos of Penetrance

Podcasts & MP3s on Penetrance

Videos on Penetrance

Evidence Based Medicine

Cochrane Collaboration on Penetrance

Bandolier on Penetrance

TRIP on Penetrance

Clinical Trials

Ongoing Trials on Penetrance at Clinical Trials.gov

Trial results on Penetrance

Clinical Trials on Penetrance at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Penetrance

NICE Guidance on Penetrance

NHS PRODIGY Guidance

FDA on Penetrance

CDC on Penetrance

Books

Books on Penetrance

News

Penetrance in the news

Be alerted to news on Penetrance

News trends on Penetrance

Commentary

Blogs on Penetrance

Definitions

Definitions of Penetrance

Patient Resources / Community

Patient resources on Penetrance

Discussion groups on Penetrance

Patient Handouts on Penetrance

Directions to Hospitals Treating Penetrance

Risk calculators and risk factors for Penetrance

Healthcare Provider Resources

Symptoms of Penetrance

Causes & Risk Factors for Penetrance

Diagnostic studies for Penetrance

Treatment of Penetrance

Continuing Medical Education (CME)

CME Programs on Penetrance

International

Penetrance en Espanol

Penetrance en Francais

Business

Penetrance in the Marketplace

Patents on Penetrance

Experimental / Informatics

List of terms related to Penetrance

Overview

Penetrance is a term used in genetics that describes the extent to which the properties controlled by a gene, its phenotype, will be expressed. For example Huntingtons disease has 95% penetrance whereby 5% of those with the dominant allele for Huntingtons don't acquire the disease and 95% do. Penetrance is the percentage of individuals with a specific genotype which possess an associated phenotype. For example, if 50% of the individuals carrying the "blue" gene are blue, the "blue" gene has 50% penetrance.

If a gene is highly penetrant, the trait it produces will always or almost always be apparent in an individual carrying the gene. A gene with low penetrance will only sometimes produce the symptom or trait with which it has been associated at a detectable level. In the case of low penetrance it is difficult to distinguish environmental from genetic factors.

Common examples used to show degrees of penetrance are often highly penetrant. There are several reasons for this:

  1. Highly penetrant genes, and highly heritable symptoms, are easier to demonstrate – if the gene is present, the phenotype is expressed (recessivity, dominance, and co-dominance are fairly simple additions to this principle);
  2. Genes which are highly penetrant are more easily noticed by geneticists, and genes for symptoms which are highly heritable are more easily inferred to exist, and then more easily tracked down.

However, relatively few of the genes in the genome show high penetrance. Traits such as height or intelligence are modified by multiple genes as well as by environmental factors. Distribution of polygenic traits often falls along a bell curve.

The penetrance of some diseases is age-related. An example is multiple endocrine neoplasia 1 (MEN 1), a disorder characterized by parathyroid hyperplasia and pancreatic islet-cell and pituitary adenomas. It is due to a mutation in the menin gene on chromosome 11q13. In one study the age-related penetrance of MEN1 was 7 percent by age 10 years and nearly 100 percent by age 60 years.

See also


References

  • Bessett JH et al. "Characterization of mutations in patients with multiple endocrine neoplasia type 1." Am J Hum Genet 1998 Feb;62(2):232-44.


Template:SIB

cs:Penetrance de:Penetranz

Template:WH Template:WikiDoc Sources